Zoetis Inc. (NYSE:ZTS) Shares Bought by Obermeyer Wealth Partners

Obermeyer Wealth Partners grew its position in Zoetis Inc. (NYSE:ZTS) by 6.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,736 shares of the company’s stock after acquiring an additional 104 shares during the quarter. Obermeyer Wealth Partners’ holdings in Zoetis were worth $283,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of ZTS. Mission Wealth Management LP boosted its stake in Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. raised its holdings in shares of Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after buying an additional 62 shares during the last quarter. HUB Investment Partners LLC boosted its stake in shares of Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock worth $224,000 after buying an additional 62 shares during the period. Procyon Advisors LLC boosted its stake in shares of Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares during the period. Finally, Coppell Advisory Solutions LLC grew its holdings in shares of Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock worth $68,000 after buying an additional 64 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Zoetis stock opened at $160.43 on Wednesday. The company has a market cap of $71.42 billion, a P/E ratio of 29.33, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The business has a fifty day moving average of $157.03 and a two-hundred day moving average of $165.79. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.38 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ZTS. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.